JP2020520382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520382A5 JP2020520382A5 JP2020513491A JP2020513491A JP2020520382A5 JP 2020520382 A5 JP2020520382 A5 JP 2020520382A5 JP 2020513491 A JP2020513491 A JP 2020513491A JP 2020513491 A JP2020513491 A JP 2020513491A JP 2020520382 A5 JP2020520382 A5 JP 2020520382A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022195529A JP2023016969A (ja) | 2017-05-12 | 2022-12-07 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505558P | 2017-05-12 | 2017-05-12 | |
| US62/505,558 | 2017-05-12 | ||
| PCT/US2018/032559 WO2018209346A1 (en) | 2017-05-12 | 2018-05-14 | Use of anti-b7h3 antibodies for treating cancer in the central nervous system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195529A Division JP2023016969A (ja) | 2017-05-12 | 2022-12-07 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520382A JP2020520382A (ja) | 2020-07-09 |
| JP2020520382A5 true JP2020520382A5 (https=) | 2021-07-26 |
Family
ID=64102794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513491A Pending JP2020520382A (ja) | 2017-05-12 | 2018-05-14 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
| JP2022195529A Pending JP2023016969A (ja) | 2017-05-12 | 2022-12-07 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195529A Pending JP2023016969A (ja) | 2017-05-12 | 2022-12-07 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200197546A1 (https=) |
| EP (1) | EP3635012A4 (https=) |
| JP (2) | JP2020520382A (https=) |
| KR (1) | KR20200008580A (https=) |
| CN (1) | CN110799542A (https=) |
| AU (1) | AU2018265888A1 (https=) |
| BR (1) | BR112019023776A2 (https=) |
| CA (1) | CA3062335A1 (https=) |
| EA (1) | EA201992683A1 (https=) |
| RU (1) | RU2019140833A (https=) |
| WO (1) | WO2018209346A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185897A1 (en) * | 2019-03-11 | 2020-09-17 | Biocompatibles Uk Limited | Radioactive microshperes for the treatment of cns tumours |
| WO2021037319A1 (en) | 2019-08-30 | 2021-03-04 | Y-Mabs Therapeutics, Inc. | Immunohistochemical assessment of b7-h3 expression |
| WO2021190586A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | B7h3抗体-依喜替康类似物偶联物及其医药用途 |
| CN117024591A (zh) * | 2020-04-22 | 2023-11-10 | 复星凯特生物科技有限公司 | 抗人b7-h3的单克隆抗体及其应用 |
| US20230293738A1 (en) * | 2020-04-24 | 2023-09-21 | Y-Mabs Therapeutics, Inc. | B7H3 Antibodies with Chelators |
| CN112961242B (zh) * | 2020-06-30 | 2022-01-04 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| WO2022167052A1 (en) * | 2021-02-08 | 2022-08-11 | Y-Mabs Therapeutics, Inc. | Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies |
| MX2023008895A (es) | 2021-02-09 | 2023-08-09 | Medilink Therapeutics Suzhou Co Ltd | Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo. |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| WO2022232392A2 (en) * | 2021-04-28 | 2022-11-03 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| CN116867805A (zh) * | 2021-09-27 | 2023-10-10 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体蛋白质及其应用 |
| CN118647408A (zh) | 2022-02-16 | 2024-09-13 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
| EP4527415A1 (en) | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| CN119744270A (zh) * | 2022-07-08 | 2025-04-01 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体融合蛋白及其应用 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| JP2010523478A (ja) * | 2007-03-22 | 2010-07-15 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | モノクローナル抗体８ｈ９の使用 |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| KR102485788B1 (ko) * | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| US9963509B2 (en) * | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
-
2018
- 2018-05-14 CN CN201880040310.2A patent/CN110799542A/zh active Pending
- 2018-05-14 EA EA201992683A patent/EA201992683A1/ru unknown
- 2018-05-14 EP EP18797639.4A patent/EP3635012A4/en not_active Withdrawn
- 2018-05-14 BR BR112019023776-3A patent/BR112019023776A2/pt unknown
- 2018-05-14 US US16/613,028 patent/US20200197546A1/en not_active Abandoned
- 2018-05-14 CA CA3062335A patent/CA3062335A1/en active Pending
- 2018-05-14 KR KR1020197036884A patent/KR20200008580A/ko not_active Ceased
- 2018-05-14 AU AU2018265888A patent/AU2018265888A1/en not_active Abandoned
- 2018-05-14 JP JP2020513491A patent/JP2020520382A/ja active Pending
- 2018-05-14 RU RU2019140833A patent/RU2019140833A/ru unknown
- 2018-05-14 WO PCT/US2018/032559 patent/WO2018209346A1/en not_active Ceased
-
2022
- 2022-12-07 JP JP2022195529A patent/JP2023016969A/ja active Pending
-
2024
- 2024-01-24 US US18/421,157 patent/US20240415990A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520382A5 (https=) | ||
| RU2019140833A (ru) | Применение антител против в7н3 для лечения злокачественных опухолей в центральной нервной системе | |
| AU2017264955B2 (en) | Combination of anti-PD-1 antibodies and radiation to treat cancer | |
| Milenic et al. | α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2 | |
| JP2023016969A5 (https=) | ||
| Sharkey et al. | Cancer radioimmunotherapy | |
| JP7274646B2 (ja) | 血液悪性疾患を処置するための低用量抗体に基づく方法 | |
| JP2020512281A5 (https=) | ||
| JP6590985B2 (ja) | 抗原発現を上方制御するための方法 | |
| JP2023165952A (ja) | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 | |
| US20230248855A1 (en) | Her3 radioimmunotherapy for the treatment of solid cancers | |
| JP2021506817A5 (https=) | ||
| Illidge et al. | Radioimmunotherapy in follicular lymphoma | |
| Skarbnik et al. | Radioimmunotherapy in mantle cell lymphoma | |
| US20250281654A1 (en) | Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents | |
| Almqvist et al. | Biodistribution of 211At-labeled humanized monoclonal antibody A33 | |
| Cona et al. | Continuing pursuit for ideal systemic anticancer radiotherapeutics | |
| JP2023550462A (ja) | 固形がんの治療のためのｈｅｒ３放射免疫治療薬 | |
| JP2008540429A (ja) | 癌の治療における併用療法 | |
| Rathmann | Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry | |
| Mitra et al. | Passive antibody-mediated immunotherapy for the treatment of malignant gliomas | |
| US20190192701A1 (en) | Method for tumor-targeting treatment and diagnosis, conjugates used for the same, and preparation method thereof | |
| US12551584B1 (en) | Lewis Y radioimmunotherapy for the treatment of cancer | |
| WO2012032043A1 (en) | 212 pb imaging | |
| Rana et al. | Radioimmunotherapy-An Overview |